Bala Cynwyd, PA-based Duska Therapeutics has raised $5.75 million in financing from three institutional investors. The company also announced that James S. Kuo, M.D., M.B.A., is the company's new CEO. He also serves as Duska's board chairman, and previously was CEO of BioMicro Systems. Duska is focused on developing new medicines to treat cardiovascular disease by modulating the P2 receptor in the heart and lungs.
"We are excited to complete this first financing by institutional investors. We intend to use the proceeds to develop several of our drugs to an inflection point in valuation," said Kuo.
The top five VC deals of 2007. Report